Ginkgo Bioworks Holdings Inc vs DENTSPLY SIRONA Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while DENTSPLY SIRONA Inc trades at $12.5 (market cap $2.55B). The key difference: DENTSPLY SIRONA Inc is far larger — about 4.3× Ginkgo Bioworks Holdings Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | XRAY | |
|---|---|---|
Market Cap | $590.53M | $2.55B |
Sector | Health | Health |
52-Week High | $16.14 | $16.85 |
52-Week Low | $5.48 | $9.64 |
Enterprise Value | $627.78M | $4.69B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Dentsply Sirona (XRAY) trades at $12.78, up 4.24% today, with technical indicators showing bullish momentum despite recent earnings misses. The company faces fundamental challenges with negative net income margins (-17.06%) and declining revenue trends, though it maintains a solid gross margin of 48.93%. Recent developments include new CFO appointment and expanded distribution partnerships, while analyst consensus remains mixed with a $13.33 price target.
The stock presents a turnaround opportunity with improving cash flow trends and strategic initiatives, but faces significant execution risks amid persistent profitability challenges. Near-term catalysts include Q2 2026 earnings and continued progress on the Return-to-Growth plan, though high debt levels and competitive pressures warrant caution for investors.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →